Evolent Health/$EVH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Evolent Health

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Ticker

$EVH

Primary listing

NYSE

Industry

Health Care Technology

Employees

4,500

ISIN

US30050B1017

Evolent Health Metrics

BasicAdvanced
$984M
-
-$1.22
1.04
-

What the Analysts think about Evolent Health

Analyst ratings (Buy, Hold, Sell) for Evolent Health stock.

Bulls say / Bears say

Evolent Health's recent acquisition of IPG for $375 million is expected to enhance its position in value-based specialty care and diversify its customer mix, potentially leading to increased revenue streams. (stocktitan.net)
The company's integration of advanced AI technology through the acquisition of Machinify's assets aims to streamline clinical review processes, improving efficiency and patient outcomes, which could drive future growth. (stocktitan.net)
Analysts have maintained a 'Strong Buy' rating for Evolent Health, with a 12-month price target of $16.71, indicating a potential upside of over 60% from the current price. (stockanalysis.com)
Evolent Health reported a net loss of $23.14 million in Q3 2024, despite revenue growth, raising concerns about its profitability and financial stability. (simplywall.st)
The company's return on equity stands at -7.02%, indicating inefficiencies in generating profits from shareholders' equity, which may deter potential investors. (valueresearchonline.com)
Evolent Health's stock price has declined by approximately 6.72% year-to-date, underperforming compared to broader market indices, which could reflect investor skepticism about its growth prospects. (valueresearchonline.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Evolent Health Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Evolent Health Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EVH

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs